515 related articles for article (PubMed ID: 16116250)
1. Mechanisms of broad cross-protection provided by influenza virus infection and their application to vaccines.
Tamura S; Tanimoto T; Kurata T
Jpn J Infect Dis; 2005 Aug; 58(4):195-207. PubMed ID: 16116250
[TBL] [Abstract][Full Text] [Related]
2. Defense mechanisms against influenza virus infection in the respiratory tract mucosa.
Tamura S; Kurata T
Jpn J Infect Dis; 2004 Dec; 57(6):236-47. PubMed ID: 15623947
[TBL] [Abstract][Full Text] [Related]
3. Secretory IgA antibodies provide cross-protection against infection with different strains of influenza B virus.
Asahi-Ozaki Y; Yoshikawa T; Iwakura Y; Suzuki Y; Tamura S; Kurata T; Sata T
J Med Virol; 2004 Oct; 74(2):328-35. PubMed ID: 15332283
[TBL] [Abstract][Full Text] [Related]
4. Cross-protection against influenza virus infection afforded by trivalent inactivated vaccines inoculated intranasally with cholera toxin B subunit.
Tamura S; Ito Y; Asanuma H; Hirabayashi Y; Suzuki Y; Nagamine T; Aizawa C; Kurata T
J Immunol; 1992 Aug; 149(3):981-8. PubMed ID: 1634780
[TBL] [Abstract][Full Text] [Related]
5. [Intranasal inactivated influenza vaccine].
Tamura S
Nihon Rinsho; 2006 Oct; 64(10):1871-8. PubMed ID: 17037362
[TBL] [Abstract][Full Text] [Related]
6. Heterosubtypic immunity against human influenza A viruses, including recently emerged avian H5 and H9 viruses, induced by FLU-ISCOM vaccine in mice requires both cytotoxic T-lymphocyte and macrophage function.
Sambhara S; Kurichh A; Miranda R; Tumpey T; Rowe T; Renshaw M; Arpino R; Tamane A; Kandil A; James O; Underdown B; Klein M; Katz J; Burt D
Cell Immunol; 2001 Aug; 211(2):143-53. PubMed ID: 11591118
[TBL] [Abstract][Full Text] [Related]
7. Superior cross-protective effect of nasal vaccination to subcutaneous inoculation with influenza hemagglutinin vaccine.
Tamura SI; Asanuma H; Ito Y; Hirabayashi Y; Suzuki Y; Nagamine T; Aizawa C; Kurata T; Oya A
Eur J Immunol; 1992 Feb; 22(2):477-81. PubMed ID: 1537382
[TBL] [Abstract][Full Text] [Related]
8. Protection against influenza virus infection by intranasal vaccine with surf clam microparticles (SMP) as an adjuvant.
Ichinohe T; Watanabe I; Tao E; Ito S; Kawaguchi A; Tamura S; Takahashi H; Sawa H; Moriyama M; Chiba J; Komase K; Suzuki Y; Kurata T; Sata T; Hasegawa H
J Med Virol; 2006 Jul; 78(7):954-63. PubMed ID: 16721854
[TBL] [Abstract][Full Text] [Related]
9. Studies on the usefulness of intranasal inactivated influenza vaccines.
Tamura S
Vaccine; 2010 Aug; 28(38):6393-7. PubMed ID: 20493820
[TBL] [Abstract][Full Text] [Related]
10. Intranasal Inactivated Influenza Vaccines: a Reasonable Approach to Improve the Efficacy of Influenza Vaccine?
Tamura S; Ainai A; Suzuki T; Kurata T; Hasegawa H
Jpn J Infect Dis; 2016; 69(3):165-79. PubMed ID: 27212584
[TBL] [Abstract][Full Text] [Related]
11. Cross-protection against influenza A virus infection by passively transferred respiratory tract IgA antibodies to different hemagglutinin molecules.
Tamura S; Funato H; Hirabayashi Y; Suzuki Y; Nagamine T; Aizawa C; Kurata T
Eur J Immunol; 1991 Jun; 21(6):1337-44. PubMed ID: 1646112
[TBL] [Abstract][Full Text] [Related]
12. Pandemic preparedness: toward a universal influenza vaccine.
Roose K; Fiers W; Saelens X
Drug News Perspect; 2009 Mar; 22(2):80-92. PubMed ID: 19330167
[TBL] [Abstract][Full Text] [Related]
13. Cross-protection in mice infected with influenza A virus by the respiratory route is correlated with local IgA antibody rather than serum antibody or cytotoxic T cell reactivity.
Liew FY; Russell SM; Appleyard G; Brand CM; Beale J
Eur J Immunol; 1984 Apr; 14(4):350-6. PubMed ID: 6609824
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms of heterosubtypic immunity to lethal influenza A virus infection in fully immunocompetent, T cell-depleted, beta2-microglobulin-deficient, and J chain-deficient mice.
Epstein SL; Lo CY; Misplon JA; Lawson CM; Hendrickson BA; Max EE; Subbarao K
J Immunol; 1997 Feb; 158(3):1222-30. PubMed ID: 9013963
[TBL] [Abstract][Full Text] [Related]
15. TH cells primed during influenza virus infection provide help for qualitatively distinct antibody responses to subsequent immunization.
Marshall D; Sealy R; Sangster M; Coleclough C
J Immunol; 1999 Nov; 163(9):4673-82. PubMed ID: 10528164
[TBL] [Abstract][Full Text] [Related]
16. Protection of chickens against H5N1 highly pathogenic avian influenza virus infection by live vaccination with infectious laryngotracheitis virus recombinants expressing H5 hemagglutinin and N1 neuraminidase.
Pavlova SP; Veits J; Keil GM; Mettenleiter TC; Fuchs W
Vaccine; 2009 Jan; 27(5):773-85. PubMed ID: 19041677
[TBL] [Abstract][Full Text] [Related]
17. Synthetic double-stranded RNA poly(I:C) combined with mucosal vaccine protects against influenza virus infection.
Ichinohe T; Watanabe I; Ito S; Fujii H; Moriyama M; Tamura S; Takahashi H; Sawa H; Chiba J; Kurata T; Sata T; Hasegawa H
J Virol; 2005 Mar; 79(5):2910-9. PubMed ID: 15709010
[TBL] [Abstract][Full Text] [Related]
18. A CTL-based liposomal vaccine capable of inducing protection against heterosubtypic influenza viruses in HLA-A*0201 transgenic mice.
Matsui M; Kohyama S; Suda T; Yokoyama S; Mori M; Kobayashi A; Taneichi M; Uchida T
Biochem Biophys Res Commun; 2010 Jan; 391(3):1494-9. PubMed ID: 20060099
[TBL] [Abstract][Full Text] [Related]
19. Beta 2-microglobulin-deficient mice can be protected against influenza A infection by vaccination with vaccinia-influenza recombinants expressing hemagglutinin and neuraminidase.
Epstein SL; Misplon JA; Lawson CM; Subbarao EK; Connors M; Murphy BR
J Immunol; 1993 Jun; 150(12):5484-93. PubMed ID: 8390536
[TBL] [Abstract][Full Text] [Related]
20. Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant.
Prabakaran M; Velumani S; He F; Karuppannan AK; Geng GY; Yin LK; Kwang J
Virology; 2008 Oct; 380(2):412-20. PubMed ID: 18786689
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
